Your browser doesn't support javascript.
loading
Differently expressed microRNA in response to the first Ig replacement therapy in common variable immunodeficiency patients.
De Felice, Bruna; Nigro, Ersilia; Polito, Rita; Rossi, Francesca Wanda; Pecoraro, Antonio; Spadaro, Giuseppe; Daniele, Aurora.
Afiliação
  • De Felice B; Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche (DISTABIF), Università della Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100, Caserta, Italy. bruna.defelice@unicampania.it.
  • Nigro E; Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche (DISTABIF), Università della Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100, Caserta, Italy.
  • Polito R; CEINGE-Biotecnologie Avanzate Scarl, Via G. Salvatore 486, 80145, Napoli, Italy.
  • Rossi FW; Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche (DISTABIF), Università della Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100, Caserta, Italy.
  • Pecoraro A; CEINGE-Biotecnologie Avanzate Scarl, Via G. Salvatore 486, 80145, Napoli, Italy.
  • Spadaro G; Department of Translational Medical Sciences (DiSMeT), Naples, Italy.
  • Daniele A; Dipartmento di Scienze Mediche e Chirurgiche Avanzate, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Sci Rep ; 10(1): 21482, 2020 12 08.
Article em En | MEDLINE | ID: mdl-33293557
ABSTRACT
Common variable immunodeficiency (CVID) is a complex primary immunodeficiency disorder characterized by a high clinical and genetic heterogeneity. The molecular underlying causes of CVID are not still now clear and the delays in diagnosis and treatment worsen the prognosis of the patients. MicroRNAs are non-coding, endogenous small RNAs often deregulated in human diseases, such as autoimmune and other immune-based disorders. In the present study, we aimed to evaluate miRNAs associated with the CVID and, in particular, with the response to the first Ig replacement therapy. To this aim, we compared miRNA profile obtained by serum samples of treatment-naïve CVID patients before and 24 h after the first Ig replacement therapy. For the first time, using a microarray assay followed by an integrated bioinformatics/biostatistics analysis, we identified five microRNAs (hsa-miR-6742, hsa-miR-1825, hsa-miR-4769-3p, hsa-miR-1228-3p, hsa-miR-1972) differently modulated in CVID patients by Ig infusion. All of them were down-regulated, excepted miR-6742 which was up-regulated. The latter may be of particular interest, since its functions are related to pathways involving Class I MHC mediated antigen processing and adaptive as well as innate Immune System. In conclusion, this study shows for the first time the modulation of miRNAs involved in CVID patients after the first Ig replacement therapy. Further studies are needed to assess whether such miRNAs could represent novel potential biomarkers in management and therapy of CVID patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Imunodeficiência de Variável Comum / MicroRNAs Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulinas / Imunodeficiência de Variável Comum / MicroRNAs Idioma: En Ano de publicação: 2020 Tipo de documento: Article